Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Alcohol use disorder (AUD) represents a serious public health issue, and discovery of new therapies is a pressing necessity. Alcohol exposure has been widely demonstrated to modulate epigenetic mechanisms, such as histone acetylation/deacetylation balance, in part via histone deacetylase (HDAC) inhibition. Epigenetic factors have been suggested to play a key role in AUD. To date, 18 different mammalian HDAC isoforms have been identified, and these have been divided into four classes. Since recent studies have suggested that both epigenetic mechanisms underlying AUD and the efficacy of HDAC inhibitors (HDACIs) in different animal models of AUD may involve class I HDACs, we herein report the development of class I HDACIs, including information regarding their structure, potency, and selectivity. More effort is required to improve the selectivity, pharmacokinetics, and toxicity profiles of HDACIs to achieve a better understanding of their efficacy in reducing addictive behavior.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For this reason, RGFP966 (Figure 11) has emerged as the most frequently employed tool for HDAC3 pharmacologic inhibition in biological studies [9, 13, 67, 69–71].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [67]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
UniProt: a hub for protein information
The UniProt Consortium (2015) · Nucleic Acids Research · doi:10.1093/nar/gku989 · Cited by 5,106
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Eberharter, A., & Becker, P. B. (2002) · EMBO reports · doi:10.1093/embo-reports/kvf053 · Cited by 948
(2002) · PubMed · Cited by 732
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle
Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., et al. (2012) · Nature · doi:10.1038/nature11316 · Cited by 577
The ESEMeD/MHEDEA 2000 investigators, Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., de Graaf, R., Demyttenaere, K., et al. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00330.x · Cited by 519
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Brain Chromatin Remodeling: A Novel Mechanism of Alcoholism
Pandey, S. C., Ugale, R., Zhang, H., Tang, L., & Prakash, A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5731-07.2008 · Cited by 373
Inside HDAC with HDAC inhibitors
Bertrand, P. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.02.030 · Cited by 363
Distribution of histone deacetylases 1–11 in the rat brain
Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., & Winrow, C. J. (2007) · Journal of Molecular Neuroscience · doi:10.1007/bf02686117 · Cited by 347
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Inside HDACs with more selective HDAC inhibitors
Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 312
The functional interactome landscape of the human histone deacetylase family
Joshi, P., Greco, T. M., Guise, A. J., Luo, Y., Yu, F., Nesvizhskii, A. I., & Cristea, I. M. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.26 · Cited by 289
Shen, S., & Kozikowski, A. P. (2016) · ChemMedChem · doi:10.1002/cmdc.201500486 · Cited by 288
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.091 · Cited by 261
Schuetz, A., Min, J., Allali-Hassani, A., Schapira, M., Shuen, M., Loppnau, P., Mazitschek, R., Kwiatkowski, N. P., Lewis, T. A., Maglathin, R. L., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707362200 · Cited by 257
Simonini, M. V., Camargo, L. M., Dong, E., Maloku, E., Veldic, M., Costa, E., & Guidotti, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510341103 · Cited by 229
Epigenetic treatment of solid tumours: a review of clinical trials
Nervi, C., De Marinis, E., & Codacci-Pisanelli, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0157-2 · Cited by 213
FINNEY, J. W., HAHN, A. C., & MOOS, R. H. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.911217733.x · Cited by 207
Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 192
Histone deacetylases: structural determinants of inhibitor selectivity
Micelli, C., & Rastelli, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.007 · Cited by 192
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191
Prevalence of and Potential Influencing Factors for Alcohol Dependence in Europe
Rehm, J., Anderson, P., Barry, J., Dimitrov, P., Elekes, Z., Feijão, F., Frick, U., Gual, A., Gmel, Jr., Kraus, L., et al. (2015) · European Addiction Research · doi:10.1159/000365284 · Cited by 183
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171
Jia, H., Pallos, J., Jacques, V., Lau, A., Tang, B., Cooper, A., Syed, A., Purcell, J., Chen, Y., Sharma, S., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.016 · Cited by 169
Alaux-Cantin, S., Warnault, V., Legastelois, R., Botia, B., Pierrefiche, O., Vilpoux, C., & Naassila, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.007 · Cited by 167
Moradei, O. M., Mallais, T. C., Frechette, S., Paquin, I., Tessier, P. E., Leit, S. M., Fournel, M., Bonfils, C., Trachy-Bourget, M.-C., Liu, J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701079h · Cited by 166
Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300837y · Cited by 165
Chromatin remodeling — a novel strategy to control excessive alcohol drinking
Warnault, V, Darcq, E., Levine, A., Barak, S., & Ron, D. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.4 · Cited by 165
Whitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., Grob, J. E., McRiner, A., Pancost, M. R., Patnaik, A., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.030 · Cited by 164
Loss of Histone Deacetylase 2 Improves Working Memory and Accelerates Extinction Learning
Morris, M. J., Mahgoub, M., Na, E. S., Pranav, H., & Monteggia, L. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1001-12.2013 · Cited by 163
Li, Z., & Zhu, W.-G. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9067 · Cited by 160
Moonat, S., Sakharkar, A. J., Zhang, H., Tang, L., & Pandey, S. C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.012 · Cited by 156
Medication treatment of different types of alcoholism
Johnson, B. A. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.08101500 · Cited by 151
Beraha, E. M., Salemink, E., Goudriaan, A. E., Bakker, A., de Jong, D., Smits, N., Zwart, J. W., van Geest, D., Bodewits, P., Schiphof, T., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.006 · Cited by 148
Schroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., Barker, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071323 · Cited by 146
Rai, M., Soragni, E., Chou, C. J., Barnes, G., Jones, S., Rusche, J. R., Gottesfeld, J. M., & Pandolfo, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008825 · Cited by 144
Wang, D.-F., Wiest, O., Helquist, P., Lan-Hargest, H.-Y., & Wiech, N. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0498497 · Cited by 141
A Proton-Shuttle Reaction Mechanism for Histone Deacetylase 8 and the Catalytic Role of Metal Ions
Wu, R., Wang, S., Zhou, N., Cao, Z., & Zhang, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja103932d · Cited by 134
Sakharkar, A. J., Zhang, H., Tang, L., Shi, G., & Pandey, S. C. (2012) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01581.x · Cited by 131
Prospective study of alcoholism treatment
Vaillant, G. E., Clark, W. D., Cyrus, C., Milofsky, E. S., Kopp, J. B., Wulsin, V. W., & Mogielnicki, N. P. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90349-2 · Cited by 125
Kozikowski, A. P., Chen, Y., Gaysin, A., Chen, B., D'Annibale, M. A., Suto, C. M., & Langley, B. C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070178x · Cited by 118
HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand?
Whittle, N., & Singewald, N. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130233 · Cited by 117
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation
Frumm, S. M., Fan, Z. P., Ross, K. N., Duvall, J. R., Gupta, S., VerPlank, L., Suh, B.-C., Holson, E., Wagner, F. F., Smith, W. B., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.020 · Cited by 112
Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0117 · Cited by 111
Wang, C., Schroeder, F. A., Wey, H., Borra, R., Wagner, F. F., Reis, S. A., Kim, S. W., Holson, E. B., Haggarty, S. J., & Hooker, J. M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500872p · Cited by 110
Pharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
Corminboeuf, C., Hu, P., Tuckerman, M. E., & Zhang, Y. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0600882 · Cited by 107
Investigating the Selectivity of Metalloenzyme Inhibitors
Day, J. A., & Cohen, S. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401053m · Cited by 106
Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers
Wagner, F. F., Zhang, Y.-L., Fass, D. M., Joseph, N., Gale, J. P., Weïwer, M., McCarren, P., Fisher, S. L., Kaya, T., Zhao, W.-N., et al. (2015) · Chemical Science · doi:10.1039/c4sc02130d · Cited by 104
Ononye, S. N., VanHeyst, M. D., Oblak, E. Z., Zhou, W., Ammar, M., Anderson, A. C., & Wright, D. L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400158k · Cited by 102
Suzuki, T., Kasuya, Y., Itoh, Y., Ota, Y., Zhan, P., Asamitsu, K., Nakagawa, H., Okamoto, T., & Miyata, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068669 · Cited by 101
The Epigenetic Landscape of Alcoholism
Krishnan, H. R., Sakharkar, A. J., Teppen, T. L., Berkel, T. D. M., & Pandey, S. C. (2014) · International Review of Neurobiology · doi:10.1016/b978-0-12-801311-3.00003-2 · Cited by 99
Moonat, S., Sakharkar, A. J., Zhang, H., & Pandey, S. C. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00275.x · Cited by 99
Antidepressant action of HDAC inhibition in the prefrontal cortex
Covington, H. E., Maze, I., Vialou, V., & Nestler, E. J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.030 · Cited by 97
Qiu, X., Xiao, X., Li, N., & Li, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.002 · Cited by 96
Thaler, F., & Mercurio, C. (2014) · ChemMedChem · doi:10.1002/cmdc.201300413 · Cited by 95
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93
Discovery of histone deacetylase 8 selective inhibitors
Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E., & Schreiber, S. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.134 · Cited by 92
Hooker, J. M., Kim, S. W., Alexoff, D., Xu, Y., Shea, C., Reid, A., Volkow, N., & Fowler, J. S. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn9000268 · Cited by 92
Suppression of Alcohol Dependence Using Baclofen: A 2-Year Observational Study of 100 Patients
de Beaurepaire, R. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00103 · Cited by 90
Kyzar, E. J., Floreani, C., Teppen, T. L., & Pandey, S. C. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00222 · Cited by 90
Sakharkar, A. J., Zhang, H., Tang, L., Baxstrom, K., Shi, G., Moonat, S., & Pandey, S. C. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000054 · Cited by 88
Simon‐O'Brien, E., Alaux‐Cantin, S., Warnault, V., Buttolo, R., Naassila, M., & Vilpoux, C. (2015) · Addiction Biology · doi:10.1111/adb.12161 · Cited by 85
Ooteman, W., Naassila, M., Koeter, M. W. J., Verheul, R., Schippers, G. M., Houchi, H., Daoust, M., & Van Den Brink, W. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2009.00159.x · Cited by 80
Structural basis for the design and synthesis of selective HDAC inhibitors
Micco, S. D., Chini, M. G., Terracciano, S., Bruno, I., Riccio, R., & Bifulco, G. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.04.036 · Cited by 80
Wagner, F. F., Weïwer, M., Steinbacher, S., Schomburg, A., Reinemer, P., Gale, J. P., Campbell, A. J., Fisher, S. L., Zhao, W., Reis, S. A., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.040 · Cited by 79
D’Addario, C., Caputi, F. F., Ekström, T. J., Benedetto, M. D., Maccarrone, M., Romualdi, P., & Candeletti, S. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9829-y · Cited by 78
Development of a Potent and Selective HDAC8 Inhibitor
Ingham, O. J., Paranal, R. M., Smith, W. B., Escobar, R. A., Yueh, H., Snyder, T., Porco, J. A., Bradner, J. E., & Beeler, A. B. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00239 · Cited by 77
Huang, W., Wang, Y., Chao, S., Yang, C., Chen, L., Lin, M., Hou, W., Chen, M., Lee, T., Yang, P., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200300 · Cited by 76
Suzuki, T., Muto, N., Bando, M., Itoh, Y., Masaki, A., Ri, M., Ota, Y., Nakagawa, H., Iida, S., Shirahige, K., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300414 · Cited by 71
Botia, B., Legastelois, R., Alaux-Cantin, S., & Naassila, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047527 · Cited by 68
General Base–General Acid Catalysis in Human Histone Deacetylase 8
Gantt, S. M. L., Decroos, C., Lee, M. S., Gullett, L. E., Bowman, C. M., Christianson, D. W., & Fierke, C. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01327 · Cited by 67
Legastelois, R., Botia, B., & Naassïla, M. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12088 · Cited by 66
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
Kumar, S. K., Tandon, N., & Ramakrishnan, V. G. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s94021 · Cited by 66
Jeanblanc, J., Lemoine, S., Jeanblanc, V., Alaux‐Cantin, S., & Naassïla, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv029 · Cited by 63
Self-citationImage-Guided Synthesis Reveals Potent Blood-Brain Barrier Permeable Histone Deacetylase Inhibitors
Seo, Y. J., Kang, Y., Muench, L., Reid, A., Caesar, S., Jean, L., Wagner, F., Holson, E., Haggarty, S. J., Weiss, P., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500021p · Cited by 61
Azetidinones as Zinc‐Binding Groups to Design Selective HDAC8 Inhibitors
Galletti, P., Quintavalla, A., Ventrici, C., Giannini, G., Cabri, W., Penco, S., Gallo, G., Vincenti, S., & Giacomini, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900309 · Cited by 61
Inhibition and Mechanism of HDAC8 Revisited
Chen, K., Zhang, X., Wu, Y.-D., & Wiest, O. (2014) · Journal of the American Chemical Society · doi:10.1021/ja501548p · Cited by 61
Sakharkar, A. J., Tang, L., Zhang, H., Chen, Y., Grayson, D. R., & Pandey, S. C. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714001047 · Cited by 57
Vanommeslaeghe, K., Proft, F. D., Loverix, S., Tourwé, D., & Geerlings, P. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.001 · Cited by 56
Marson, C. M., Matthews, C. J., Atkinson, S. J., Lamadema, N., & Thomas, N. S. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00545 · Cited by 56
Acute Ethanol Alters Multiple Histone Modifications at Model Gene Promoters in the Cerebral Cortex
Finegersh, A., & Homanics, G. E. (2014) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12465 · Cited by 52
Wambua, M. K., Nalawansha, D. A., Negmeldin, A. T., & Pflum, M. K. H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401837e · Cited by 52
Chen, Y., He, R., Chen, Y., D'Annibale, M. A., Langley, B., & Kozikowski, A. P. (2009) · ChemMedChem · doi:10.1002/cmdc.200800461 · Cited by 51
The Class I HDAC inhibitor RGFP963 enhances consolidation of cued fear extinction
Bowers, M. E., Xia, B., Carreiro, S., & Ressler, K. J. (2015) · Learning & Memory · doi:10.1101/lm.036699.114 · Cited by 50
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors
Hamblett, C. L., Methot, J. L., Mampreian, D. M., Sloman, D. L., Stanton, M. G., Kral, A. M., Fleming, J. C., Cruz, J. C., Chénard, M., Ozerova, N. D. S., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.023 · Cited by 49
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2)
Methot, J. L., Hamblett, C. L., Mampreian, D. M., Jung, J. O., Harsch, A., Szewczak, A. A., Dahlberg, W. K., Middleton, R. E., Hughes, B. L., Fleming, J. C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.052 · Cited by 47
Lin, H., Geng, X., Dang, W., Wu, B., Dai, Z., Li, Y., Yang, Y., Zhang, H., & Shi, J. (2012) · Brain Research · doi:10.1016/j.brainres.2012.01.053 · Cited by 47
Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Gupta, P., C. Reid, R., Iyer, A., J. Sweet, M., & P. Fairlie, D. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612802652420 · Cited by 47
Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor
Zhou, J., Li, M., Chen, N., Wang, S., Luo, H.-B., Zhang, Y., & Wu, R. (2015) · ACS Chemical Biology · doi:10.1021/cb500767c · Cited by 45
JONES, P. G., & Steinkühler, C. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208783885317 · Cited by 43
Histone Deacetylase Gene Expression Following Binge Alcohol Consumption in Rats and Humans
López‐Moreno, J. A., Marcos, M., Calleja‐Conde, J., Echeverry‐Alzate, V., Bühler, K., Costa‐Alba, P., Bernardo, E., Laso, F. J., de Fonseca, F. R., Nadal, R. A., et al. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12850 · Cited by 43
Pelissier, F., de Haro, L., Cardona, F., Picot, C., Puskarczyk, E., Sapori, J.-M., Tournoud, C., & Franchitto, N. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1284330 · Cited by 43
Beconi, M., Aziz, O., Matthews, K., Moumné, L., O’Connell, C., Yates, D., Clifton, S., Pett, H., Vann, J., Crowley, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044498 · Cited by 42
Design of novel histone deacetylase inhibitors
Siliphaivanh, P., Harrington, P., Witter, D. J., Otte, K. M., Tempest, P. A., Kattar, S. D., Kral, A. M., Fleming, J. C., Deshmukh, S. V., Harsch, A., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.080 · Cited by 42
HDAC Inhibitors-New Generation of Target Specific Treatment
V. Chavan, A., & R. Somani, R. (2010) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575110091263 · Cited by 40
Brewer, C. L., Streel, E., & Skinner, M. D. (2016) · Alcohol and Alcoholism · doi:10.1093/alcalc/agw093 · Cited by 40
Wang, C., Eessalu, T. E., Barth, V., Mitch, C. H., Wagner, F. F., Hong, Y., Neelamegam, R., Schroeder, F. A., Holson, E. B., Haggarty, S. J., et al. (2013) · Europe PMC (PubMed Central) · Cited by 39
The Use of Very High-Doses of Baclofen for the Treatment of Alcohol-Dependence: A Case Series
de Beaurepaire, R. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00143 · Cited by 37
Deardorff, M. A., Porter, N. J., & Christianson, D. W. (2016) · Protein Science · doi:10.1002/pro.3030 · Cited by 37
The Pharmacotherapy of Alcohol Dependence: A State of the Art Review
Sousa, A. D. (2010) · Mens Sana monographs · doi:10.4103/0973-1229.58820 · Cited by 32
Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor
Methot, J. L., Hoffman, D. M., Witter, D. J., Stanton, M. G., Harrington, P., Hamblett, C., Siliphaivanh, P., Wilson, K., Hubbs, J., Heidebrecht, R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4004233 · Cited by 31
Design and synthesis of novel hybrid benzamide–peptide histone deacetylase inhibitors
Hu, F., Chou, C. J., & Gottesfeld, J. M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.085 · Cited by 24
Heidebrecht, R. W., Chénard, M., Close, J., Dahlberg, W. K., Fleming, J. C., Grimm, J. B., Hamill, J. E., Harsch, A., Haines, B. B., Hughes, B. L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.009 · Cited by 21
Les histones désacétylases: Nouvelles cibles pour les thérapies anti-cancéreuses
Mottet, D., & Castronovo, V. (2008) · médecine/sciences · doi:10.1051/medsci/20082489742 · Cited by 19
Vaidya, A. S., Karumudi, B., Mendonca, E. L., Madriaga, A., Abdelkarim, H., van Breemen, R. B., & Petukhov, P. A. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.017 · Cited by 15
Research works printed but not linked: 6
- 2015, Global Status Report on Alcohol and Health 2014
- Polich, J. M.; Armor, D. J.; Braiker, H. B. Stability and Change in Drinking Patterns in the Course of Alcoholism: Four Years after Treatment . John Wiley & Sons: New York, 1981; pp 159–200.
- 2014, Une Recommandation Temporaire d’Utilisation (RTU) Est Accordée pour le Baclofène—Point d’Information
- Starkman B. G., 2012, Alcohol Res., 34, 293
- Wang C., 2013, Am. J. Nucl. Med. Mol. Imaging, 4, 29
- Furumai R., 2002, Cancer Res., 62, 4916
Cited by
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Zhao, C., Dong, H., Xu, Q., & Zhang, Y. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1725470 · Cited by 147
“using nonselective HDAC inhibitors should be effective against AUD and the more recent studies have shown that targeting class I HDAC is also effective in different AUD animal models [90].”
MethodDrissi, I., Deschamps, C., Fouquet, G., Alary, R., Peineau, S., Gosset, P., Sueur, H., Marcq, I., Debuysscher, V., Naassïla, M., et al. (2019) · Addiction Biology · doi:10.1111/adb.12760 · Cited by 46
“netic processes that modulate synaptic plasticity may indeed yield to novel treatments for EtOH addiction.(8,17,18) Interestingly, among the 18 isoforms of HDAC, the HDAC2 isoform seems to be particularly implicated in the effects of EtOH as EtOH‐preferring rats knockdown for HDAC2 in the amygdala showed less anxiety‐…”
BackgroundLammers, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.757179 · Cited by 44
Overview of class I HDAC modulators: Inhibitors and degraders
Huang, Z., Zeng, L., Cheng, B., & Li, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116696 · Cited by 36
Metadata
- Authors
- Bourguet, E., Ozdarska, K., Moroy, G., Jeanblanc, J., & Naassila, M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- INSERM ERi 24, Groupe de Recherche sur l’Alcool et les Pharmacodépendances (GRAP), Université de Picardie Jules Verne, C.U.R.S. (Centre Universitaire de Recherche en Santé), Chemin du Thil, 80000 Amiens, France
- Corresponding author
- Bourguet, Erika
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-08-03
- Volume
- 61
- Issue
- 5
- Pages
- 1745-1766
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2745028397
- Cited by
- 36
- References
- 113
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 3 · 2023: 8 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 2
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Minist?re de l'Enseignement Sup?rieur et de la Recherche
- Centre National de la Recherche Scientifique
- Conseil R?gional de Picardie
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- class I HDAC inhibitors, histone deacetylase, alcoholism, epigenetic therapy, histone acetylation, HDAC isoforms, structure-activity relationship, drug selectivity, pharmacokinetics, toxicity, addictive behavior
- MeSH terms
- Alcoholism, Animals, Humans, Therapeutics, Histone Deacetylase Inhibitors, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.